OBJECTIVE: To investigate the association of Clostridium difficile infection (CDI) with the outcomes of hospitalized patients with end-stage renal disease (ESRD). METHODS: We extracted all adult cases with a discharge diagnosis of ESRD or CDI from the United States Nationwide Inpatient Sample 2009 database. Outcome variables (mortality, length of hospital stay [LOS], and hospitalization charges), demographic information, and comorbidity data were collected. Data were evaluated by univariate and multiple regression analyses. RESULTS: We identified 184,139 cases with ESRD of which 2.8% had CDI. Comparison of patients with ESRD + CDI to those with only ESRD revealed in-hospital mortality (13.2% vs 5.3%; P < 0.001), LOS (17.3 vs 7.1 days; P < 0.001), and charges ($124,846 vs $56,663; P < 0.001) to be more than 2-fold greater. In the ESRD cohort (ESRD only and ESRD + CDI), CDI was independently associated with greater mortality (adjusted odds ratio, 2.15; 95% CI, 2.07-2.24; P < 0.001), longer LOS (mean difference, 9.4 days; 95% CI, 9.2-9.5; P < 0.001), and higher charges (mean difference, $62,824; 95% CI, 61,615-64,033; P < 0.001). CONCLUSIONS: Clostridium difficile infection is associated with significantly worse outcomes in hospitalized patients with ESRD.
OBJECTIVE: To investigate the association of Clostridium difficile infection (CDI) with the outcomes of hospitalized patients with end-stage renal disease (ESRD). METHODS: We extracted all adult cases with a discharge diagnosis of ESRD or CDI from the United States Nationwide Inpatient Sample 2009 database. Outcome variables (mortality, length of hospital stay [LOS], and hospitalization charges), demographic information, and comorbidity data were collected. Data were evaluated by univariate and multiple regression analyses. RESULTS: We identified 184,139 cases with ESRD of which 2.8% had CDI. Comparison of patients with ESRD + CDI to those with only ESRD revealed in-hospital mortality (13.2% vs 5.3%; P < 0.001), LOS (17.3 vs 7.1 days; P < 0.001), and charges ($124,846 vs $56,663; P < 0.001) to be more than 2-fold greater. In the ESRD cohort (ESRD only and ESRD + CDI), CDI was independently associated with greater mortality (adjusted odds ratio, 2.15; 95% CI, 2.07-2.24; P < 0.001), longer LOS (mean difference, 9.4 days; 95% CI, 9.2-9.5; P < 0.001), and higher charges (mean difference, $62,824; 95% CI, 61,615-64,033; P < 0.001). CONCLUSIONS:Clostridium difficile infection is associated with significantly worse outcomes in hospitalized patients with ESRD.
Authors: C Thongprayoon; W Cheungpasitporn; P Phatharacharukul; P J Edmonds; Q Kaewpoowat; P Mahaparn; J Bruminhent; S B Erickson Journal: Int J Clin Pract Date: 2015-07-05 Impact factor: 2.503
Authors: Łukasz Lis; Andrzej Konieczny; Michał Sroka; Anna Ciszewska; Kornelia Krakowska; Tomasz Gołębiowski; Zbigniew Hruby Journal: Antibiotics (Basel) Date: 2022-06-08
Authors: D Lachowicz; G Szulencka; P Obuch-Woszczatyński; A van Belkum; H Pituch Journal: Eur J Clin Microbiol Infect Dis Date: 2014-07-26 Impact factor: 3.267
Authors: Brandon Eilertson; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Scott Evans; Vance G Fowler; Robert A Bonomo; Jack DeHovitz; Barry Kreiswirth; David van Duin Journal: Open Forum Infect Dis Date: 2017-10-06 Impact factor: 3.835
Authors: Jacek Czepiel; Marcela Krutova; Assaf Mizrahi; Nagham Khanafer; David A Enoch; Márta Patyi; Aleksander Deptuła; Antonella Agodi; Xavier Nuvials; Hanna Pituch; Małgorzata Wójcik-Bugajska; Iwona Filipczak-Bryniarska; Bartosz Brzozowski; Marcin Krzanowski; Katarzyna Konturek; Marcin Fedewicz; Mateusz Michalak; Lorra Monpierre; Philippe Vanhems; Theodore Gouliouris; Artur Jurczyszyn; Sarah Goldman-Mazur; Dorota Wultańska; Ed J Kuijper; Jan Skupień; Grażyna Biesiada; Aleksander Garlicki Journal: Antibiotics (Basel) Date: 2021-03-13